Immunotherapy plus targeted therapy before kidney cancer surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests giving two medications (a PD-L1 inhibitor and anlotinib) before surgery for complex kidney cancer, to try to shrink the tumor enough that surgeons can remove just part of the kidney instead of the whole organ. The goal is to preserve kidney function and avoid dialysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with clear cell renal cell carcinoma (the most common type of kidney cancer)
- Cancer is stage T2–T3a (locally advanced but not spread to distant sites)
- Tumor is complex enough that it would normally require full or partial kidney removal
- Good overall health and organ function
- No prior immunotherapy or targeted therapy for kidney cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to remove a kidney tumor. The goal is to see if this approach is safe and helps shrink tumors in patients with advanced but non-spreading kidney cancer.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
This trial tests combining two drugs (cardenilimab and lenvatinib) before surgery for clear cell kidney cancer that can be removed. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.